These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 29186113)

  • 1. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.
    Germano G; Lamba S; Rospo G; Barault L; Magrì A; Maione F; Russo M; Crisafulli G; Bartolini A; Lerda G; Siravegna G; Mussolin B; Frapolli R; Montone M; Morano F; de Braud F; Amirouchene-Angelozzi N; Marsoni S; D'Incalci M; Orlandi A; Giraudo E; Sartore-Bianchi A; Siena S; Pietrantonio F; Di Nicolantonio F; Bardelli A
    Nature; 2017 Dec; 552(7683):116-120. PubMed ID: 29186113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving neoantigen profiles in colorectal cancers with DNA repair defects.
    Rospo G; Lorenzato A; Amirouchene-Angelozzi N; Magrì A; Cancelliere C; Corti G; Negrino C; Amodio V; Montone M; Bartolini A; Barault L; Novara L; Isella C; Medico E; Bertotti A; Trusolino L; Germano G; Di Nicolantonio F; Bardelli A
    Genome Med; 2019 Jun; 11(1):42. PubMed ID: 31253177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Clinical Impact of the Genomic Landscape of Mismatch Repair-Deficient Cancers.
    Germano G; Amirouchene-Angelozzi N; Rospo G; Bardelli A
    Cancer Discov; 2018 Dec; 8(12):1518-1528. PubMed ID: 30442708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of DNA mismatch repair in immunotherapy of human cancer.
    He Y; Zhang L; Zhou R; Wang Y; Chen H
    Int J Biol Sci; 2022; 18(7):2821-2832. PubMed ID: 35541922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mutational profile and infiltration pattern of murine MLH1-/- tumors: concurrences, disparities and cell line establishment for functional analysis.
    Maletzki C; Beyrich F; Hühns M; Klar E; Linnebacher M
    Oncotarget; 2016 Aug; 7(33):53583-53598. PubMed ID: 27447752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
    van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
    Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
    Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
    Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-canonical antigens are the largest fraction of peptides presented by MHC class I in mismatch repair deficient murine colorectal cancer.
    Rospo G; Chilà R; Matafora V; Basso V; Lamba S; Bartolini A; Bachi A; Di Nicolantonio F; Mondino A; Germano G; Bardelli A
    Genome Med; 2024 Jan; 16(1):15. PubMed ID: 38243308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma.
    Chae YK; Anker JF; Oh MS; Bais P; Namburi S; Agte S; Giles FJ; Chuang JH
    Sci Rep; 2019 Mar; 9(1):3235. PubMed ID: 30824826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.
    Kloor M; Huth C; Voigt AY; Benner A; Schirmacher P; von Knebel Doeberitz M; Bläker H
    Lancet Oncol; 2012 Jun; 13(6):598-606. PubMed ID: 22552011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity.
    Lu C; Guan J; Lu S; Jin Q; Rousseau B; Lu T; Stephens D; Zhang H; Zhu J; Yang M; Ren Z; Liang Y; Liu Z; Han C; Liu L; Cao X; Zhang A; Qiao J; Batten K; Chen M; Castrillon DH; Wang T; Li B; Diaz LA; Li GM; Fu YX
    Cancer Cell; 2021 Jan; 39(1):96-108.e6. PubMed ID: 33338425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome.
    Westdorp H; Kolders S; Hoogerbrugge N; de Vries IJM; Jongmans MCJ; Schreibelt G
    Cancer Lett; 2017 Sep; 403():159-164. PubMed ID: 28645564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofibromatosis type 1 gene as a mutational target in a mismatch repair-deficient cell type.
    Wang Q; Montmain G; Ruano E; Upadhyaya M; Dudley S; Liskay RM; Thibodeau SN; Puisieux A
    Hum Genet; 2003 Feb; 112(2):117-23. PubMed ID: 12522551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers.
    Zlobec I; Minoo P; Terracciano L; Baker K; Lugli A
    Histopathology; 2011 Sep; 59(3):482-95. PubMed ID: 22034888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.
    Meyers M; Wagner MW; Hwang HS; Kinsella TJ; Boothman DA
    Cancer Res; 2001 Jul; 61(13):5193-201. PubMed ID: 11431359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The First Molecular Screening of MLH1 and MSH2 Genes in Moroccan Colorectal Cancer Patients Shows a Relatively High Mutational Prevalence.
    Moufid FZ; Bouguenouch L; El Bouchikhi I; Chbani L; Iraqui Houssaini M; Sekal M; Belhassan K; Bennani B; Ouldim K
    Genet Test Mol Biomarkers; 2018 Aug; 22(8):492-497. PubMed ID: 30044143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial.
    Kloor M; Reuschenbach M; Pauligk C; Karbach J; Rafiyan MR; Al-Batran SE; Tariverdian M; Jäger E; von Knebel Doeberitz M
    Clin Cancer Res; 2020 Sep; 26(17):4503-4510. PubMed ID: 32540851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA mismatch repair deficiency in breast carcinoma: a pilot study of triple-negative and non-triple-negative tumors.
    Wen YH; Brogi E; Zeng Z; Akram M; Catalano J; Paty PB; Norton L; Shia J
    Am J Surg Pathol; 2012 Nov; 36(11):1700-8. PubMed ID: 22992699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.
    Wilczak W; Rashed S; Hube-Magg C; Kluth M; Simon R; Büscheck F; Clauditz TS; Grupp K; Minner S; Tsourlakis MC; Möller-Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Izbicki JR; Huland H; Schlomm T; Steurer S; Krech T; Lebok P
    Carcinogenesis; 2017 Jan; 38(1):19-27. PubMed ID: 27803051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.